SEK2 Recombinant Protein: From Benchside Basic Research to Clinical Translation — Powered by ANTBIO

Literature Review & Research Highlights

1. Literature Overview

This review summarizes recent advances in the preparation, structural characterization, functional dissection, and translational applications of SEK2 recombinant protein, a core kinase in the MAPK/JNK signaling pathway. The content integrates protein engineering, biochemistry, disease mechanism research, and drug discovery, providing a comprehensive reference for signal transduction and biomedical research.

2. Research Background

SEK2 (also known as MKK4) is a pivotal mitogen-activated protein kinase kinase that specifically activates JNK1/2/3 signaling. It participates in critical physiological processes including cell stress response, apoptosis, inflammation, and development. Dysregulation of SEK2 is closely associated with cancer progression, neurodegeneration, cardiovascular diseases, and autoimmune disorders.

Highly active, well‑modified, and pure SEK2 recombinant protein is essential for:

• In vitro kinase assays
• Signaling pathway reconstitution
• Protein–protein interaction analysis
• Inhibitor screening
• Clinical biomarker development
• Structural biology research

However, batch consistency, post‑translational modification, phosphorylation state control, and stability have long been technical challenges in recombinant protein production.

3. Research Strategy & Methodology

Researchers have established multiple protein expression systems to produce SEK2 with different properties for diverse experimental scenarios:

• Prokaryotic system (E. coli BL21(DE3), pET vectors)

High yield (15–20 mg/L), cost‑effective; suitable for large‑scale preparation.

• Co‑expression with MEKK1

Achieves in situ phosphorylation to generate active SEK2.

• Mammalian expression system (HEK293)

Native post‑translational modifications, low yield (2–5 mg/L), ideal for structural studies.

• Cell‑free protein synthesis

Ultra‑fast production (<24 h) and customizable phosphorylation states.

Quality control includes:

• SDS‑PAGE & HPLC (>95% purity)
• Mass spectrometry (MW verification)
• Kinase activity assay (3,000–5,000 pmol/min/mg)
• Thermal stability & circular dichroism (Tm)
• Endotoxin and aggregation detection

Various SEK2 variants have been developed: full‑length, kinase domain, tagged (His/GST/FLAG), kinase‑dead (K61R), phosphorylation‑deficient (S257A/T261A), substrate‑binding mutant (D208K), and isotope‑labeled (15N/13C) for NMR.

4. Key Research Achievements

4.1 Structural & Biochemical Insights

• Crystal structure of SEK2 kinase domain (PDB: 3ALN) solved at 2.3 Å.
• Phosphorylation induces conformational shift in the activation loop and enhances stability (ΔTm ≈ 8–10°C).
• SEK2 shows substrate preference: JNK1 > JNK2, with low activity toward JNK3.

4.2 Signaling Pathway Reconstitution

In vitro reconstitution of the ASK1–SEK2–JNK cascade revealed stoichiometry and kinetic parameters, supporting high‑throughput drug screening.

4.3 Protein–Protein Interactions

SEK2 forms stable complexes with JIP1, MKP7, and ITCH; 27 novel interactors including RNA‑binding proteins were discovered.

4.4 Post‑Translational Modifications

Phosphorylation, ubiquitination, acetylation, and SUMOylation jointly regulate SEK2 activity, linking metabolism and stress signaling.

4.5 Disease Relevance

• Cancer: SEK2 mutant phenotypes; p‑SEK2 predicts platinum response in ovarian cancer.
• Neurodegeneration: SEK2 promotes tau and α‑synuclein phosphorylation in Alzheimer’s and Parkinson’s diseases.
• Cardiovascular diseases: ox‑LDL activates SEK2‑dependent endothelial injury.
• Autoimmunity: Anti‑SEK2 autoantibodies are elevated in rheumatoid arthritis and lupus.

4.6 Drug Discovery

SEK2‑based screening identified ATP‑competitive, allosteric, and protein–protein interaction inhibitors with potent anti‑inflammatory and anti‑tumor activity.

5. How ANTBIO Empowers This Research

ANT BIO PTE. LTD. provides high‑purity, consistent‑activity, phosphorylation‑controlled SEK2 recombinant proteins that directly support all experiments mentioned above.

Our Products Enable:

• Stable in vitro kinase assays with high reproducibility
• Reliable protein–protein interaction studies (SPR, pull‑down, IP)
• Accurate screening of SEK2 inhibitors and modulators
• Quantitative calibration for clinical sample detection
• Structural biology with native‑like modification
• Consistent batch performance for long‑term projects

6. Our Mission at ANTBIO

ANT BIO PTE. LTD. is a trusted provider of high‑performance life science reagents. We focus on recombinant proteins, antibodies, ELISA kits, and general laboratory reagents to accelerate discoveries in signal transduction, oncology, immunology, and neuroscience.

Our three specialized sub‑brands support every stage of your research:

• Absin: General reagents & detection kits
• Starter: High‑specificity antibodies for WB, IHC, IF, IP
• UA: Premium recombinant proteins with validated activity

Featured Related Products from ANTBIO

Recombinant Proteins (UA Brand)

• SEK2 (MKK4) recombinant protein (active, phosphorylated)
• SEK2 kinase domain recombinant protein
• SEK2 K61R (kinase‑dead) mutant protein
• SEK2 S257A/T261A mutant protein
• JNK1 recombinant protein (substrate for SEK2)
• MEKK1 recombinant protein (upstream kinase)

Antibodies (Starter Brand)

• Anti‑SEK2 rabbit monoclonal antibody
• Anti‑phospho‑SEK2 (Ser257/Thr261) antibody
• Anti‑JIP1 antibody
• Anti‑JNK1/2/3 antibody
• Anti‑MKP7 antibody

Kits & Reagents (Absin Brand)

• SEK2 kinase activity assay kit
• JNK phosphorylation detection kit
• ELISA kit for SEK2 autoantibodies
• Universal protein stabilizer & storage buffer

Brand Promotion

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs

At ANTBIO, we are committed to advancing life science research through high‑quality, reliable reagents and comprehensive solutions. Our specialized sub‑brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer‑centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.